Takara Bio Inc. (TYO:4974)
797.00
-19.00 (-2.33%)
At close: Feb 6, 2026
Takara Bio Revenue
Takara Bio had revenue of 9.53B JPY in the quarter ending September 30, 2025, a decrease of -15.42%. This brings the company's revenue in the last twelve months to 44.08B, down -0.16% year-over-year. In the fiscal year ending March 31, 2025, Takara Bio had annual revenue of 45.04B with 3.53% growth.
Revenue (ttm)
44.08B
Revenue Growth
-0.16%
P/S Ratio
2.18
Revenue / Employee
24.78M
Employees
1,779
Market Cap
95.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 45.04B | 1.53B | 3.53% |
| Mar 31, 2024 | 43.51B | -34.64B | -44.33% |
| Mar 31, 2023 | 78.14B | 10.44B | 15.43% |
| Mar 31, 2022 | 67.70B | 21.61B | 46.90% |
| Mar 31, 2021 | 46.09B | 11.52B | 33.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 28.70B |
| GNI Group | 25.78B |
| PeptiDream | 17.93B |
| RaQualia Pharma | 3.05B |
| Japan Tissue Engineering | 2.26B |
| AnGes | 818.00M |
| Cuorips | 360.00M |
| Healios K.K. | 97.00M |